Clinically significant bleeding with immune checkpoint inhibitors: A retrospective cohort study

2020 ◽  
Vol 137 ◽  
pp. 285-287
Author(s):  
Tariq Kewan ◽  
Fahrettin Covut ◽  
Ramsha Ahmed ◽  
Abdo Haddad ◽  
Hamed Daw
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Immune Checkpoint ◽  
Retrospective Cohort ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Clinically Significant

Cutaneous Adverse Events to Immune Checkpoint Inhibitors in Pediatric Populations: A Retrospective Cohort Study

2020 ◽  
Author(s):  
Lindsay McCormack ◽  
Leah L. Thompson ◽  
Michael S. Chang ◽  
Nicole Polyakov ◽  
Hannah Song ◽  
...  
Keyword(s):  
Cohort Study ◽  
Adverse Events ◽  
Retrospective Cohort Study ◽  
Immune Checkpoint ◽  
Retrospective Cohort ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Pediatric Populations

Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study

Drug Safety ◽  
2019 ◽  
Vol 43 (2) ◽  
pp. 111-117 ◽  
Author(s):  
Samy Babai ◽  
Anne-Laure Voisin ◽  
Célia Bertin ◽  
Amandine Gouverneur ◽  
Hervé Le-Louet
Keyword(s):  
Cohort Study ◽  
Cancer Patients ◽  
Retrospective Cohort Study ◽  
Immune Checkpoint ◽  
Retrospective Cohort ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

scholarly journals MP26-19 TESTICULAR HISTOPATHOLOGY AFTER IMMUNOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS - A RETROSPECTIVE COHORT STUDY

2020 ◽  
Vol 203 ◽  
pp. e408
Author(s):  
Taylor P Kohn* ◽  
Jason Scovell ◽  
Iryna Samarska ◽  
Mahir Maruf ◽  
Eleonora Duregon ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Immune Checkpoint ◽  
Retrospective Cohort ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

scholarly journals Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study

2019 ◽  
Vol 58 (7) ◽  
pp. 953-961 ◽  
Author(s):  
Birgitte Bjørnhart ◽  
Karin H. Hansen ◽  
Trine L. Jørgensen ◽  
Jørn Herrstedt ◽  
Tine Schytte
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Real Life ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung

scholarly journals Immunotherapy toxicities in metastatic vulvar and vaginal melanomas: a retrospective cohort study

2020 ◽  
Vol 18 (2) ◽  
pp. e39-e42
Author(s):  
Sheida Naderi-Azad ◽  
◽  
Faisal Sickander ◽  
Rossanna C. Pezo ◽  
◽  
...  
Keyword(s):  
Overall Survival ◽  
Cohort Study ◽  
Adverse Events ◽  
Retrospective Cohort Study ◽  
Immune Checkpoint ◽  
Cutaneous Melanoma ◽  
Retrospective Cohort ◽  
Soft Tissues ◽  
Checkpoint Inhibitors ◽  
Significant Difference

This retrospective cohort study examined the factors for patients with metastatic vulvar and vaginal melanomas on immune checkpoint inhibitors. The study included all patients over the age of 18 who received either anti-cytotoxic T-lymphocyte-4 (anti-CTLA-4) therapy or anti-programmed cell death protein-1 (anti-PD-1) therapy at the Sunnybrook Hospital from June 2012 to December 2018. There were 11 patients with vulvar or vaginal melanoma on immune checkpoint inhibitor therapy. The main sites of metastasis included the lungs, lymph nodes, soft tissues, and liver. The majority of patients received prior radiation therapy (7/11) and prior surgical therapy (9/11). There were no differences in overall survival for vulvar or vaginal melanomas on anti-PD-1 vs. anti-CTLA-4 therapy (p > 0.05). There were no significant differences in overall survival for vulvar and vaginal vs. cutaneous melanoma (p > 0.5). There were no significant differences in overall survival in patients with vulvar and vaginal melanoma in the presence vs. absence of immune-related adverse events (p > 0.05), yet there was a significant difference in patients with cutaneous melanoma in the presence vs. absence of immune-related adverse events (p < 0.05). Knowledge of the presentation and outcome of vulvar and vaginal melanomas is important for clinical practice in gynecology.

scholarly journals Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

2020 ◽  
Vol 8 (1) ◽  
pp. e000144 ◽  
Author(s):  
Sarah Abou Alaiwi ◽  
Wanling Xie ◽  
Amin H Nassar ◽  
Shaan Dudani ◽  
Dylan Martini ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Median Time ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Safety And Efficacy ◽  
Clinically Significant

BackgroundImmune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the safety and efficacy are not yet well characterized.MethodsThis multicenter retrospective study identified patients with metastatic renal cell carcinoma treated with ICI who had >1 week therapy interruption for irAEs. Patients were classified into retreatment and discontinuation cohorts based on whether or not they resumed an ICI. Toxicity and clinical outcomes were assessed descriptively.ResultsOf 499 patients treated with ICIs, 80 developed irAEs warranting treatment interruption; 36 (45%) of whom were restarted on an ICI and 44 (55%) who permanently discontinued. Median time to initial irAE was similar between the retreatment and discontinuation cohorts (2.8 vs 2.7 months, p=0.59). The type and grade of irAEs were balanced across the cohorts; however, fewer retreatment patients required corticosteroids (55.6% vs 84.1%, p=0.007) and hospitalizations (33.3% vs 65.9%, p=0.007) for irAE management compared with discontinuation patients. Median treatment holiday before reinitiation was 0.9 months (0.2–31.6). After retreatment, 50% (n=18/36) experienced subsequent irAEs (12 new, 6 recurrent) with 7 (19%) grade 3 events and 13 drug interruptions. Median time to irAE recurrence after retreatment was 2.8 months (range: 0.3–13.8). Retreatment resulted in 6 (23.1%) additional responses in 26 patients whose disease had not previously responded. From first ICI initiation, median time to next therapy was 14.2 months (95% CI 8.2 to 18.9) and 9.0 months (5.3 to 25.8), and 2-year overall survival was 76% (95%CI 55% to 88%) and 66% (48% to 79%) in the retreatment and discontinuation groups, respectively.ConclusionsDespite a considerable rate of irAE recurrence with retreatment after a prior clinically significant irAE, most irAEs were low grade and controllable. Prospective studies are warranted to confirm that retreatment enhances survival outcomes that justify the safety risks.

scholarly journals Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory‐wide cohort study

2020 ◽  
Vol 9 (19) ◽  
pp. 7052-7061 ◽  
Author(s):  
Stephen Lam Chan ◽  
Terry Cheuk‐Fung Yip ◽  
Vincent Wai‐Sun Wong ◽  
Yee‐Kit Tse ◽  
Becky Wing‐Yan Yuen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Adverse Events ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

Thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21198-e21198
Author(s):  
Xavier Deschenes-Simard ◽  
Loik Galland ◽  
Florence Blais ◽  
Antoine Desilets ◽  
Julie Malo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

e21198 Background: Venous thromboembolism is a frequent complication of non-small cell lung cancer (NSCLC) and is associated with a worse prognosis, a reduced quality of life, and increased healthcare costs. Immune checkpoint inhibitors (ICI) are revolutionizing the management of NSCLC, but little is known about their impact on thrombosis. This study aims to define the incidence and clinical relevance of thrombosis in NSCLC patients receiving these treatments. Methods: A retrospective multicentric cohort study including 593 patients from three centers in Canada and France was performed. The cumulative incidence of venous thrombotic events after ICIs was calculated, and the impact of these events on survival and response to treatment was determined. Finally, univariate log-rank tests were performed to identify thrombosis risk factors. Results: The incidence of venous thrombosis in the cohort was 9.9% for an incidence rate of 76.5 thrombosis per 1000 person-years, with most thromboses occurring rapidly after treatment initiation. Thrombosis was not correlated with overall survival, progression-free survival, or objective response to ICIs (summarized in the table below). Age ˂ 65 years old (HR = 1.66; 95 % CI = 1.00 – 2.82) and a delay of less than 12 months from diagnosis to the first ICI treatment (HR = 1.74; 95 % CI = 1.03 – 2.87) were associated with an increased risk of thrombosis. Tumors with PD-L1 > 1% were associated with more thrombosis in the first year since the beginning of therapy (HR = 3.06; 95 % CI = 1.19 – 4.76, p=0.015). Conclusions: This study suggests that the time distribution and incidence of thrombotic events in NSCLC patients treated with ICI are comparable to what is reported in other cohorts of patients treated with chemotherapy. In our cohort, thrombosis was not a prognostic factor for survival or response to therapy. Patient age < 65 and tumors with PD-L1 > 1% were associated to a higher risk of thrombotic events.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document